Pancreatic Cancer’s Weakness Revealed

Diagnosing pancreatic cancer is arguably one of the most challenging situations in oncology. A mere 13% survival rate at five years, coupled with stubborn resistance to chemotherapy, radiation, and immunotherapy, makes it a formidable foe. What’s its secret? A remarkably elegant molecular defense system that, until now, seemed impenetrable to therapeutic attacks, as reported by New Atlas.

But researchers at Indiana University in Bloomington are changing that narrative. they’ve identified an unexpected vulnerability: a protein pair – REF-1 and PRDX1 – that work together to keep the tumor thriving and resistant to treatment. REF-1 essentially acts as a driver of cancer genes, while PRDX1 shields it from cellular stress.